Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome
- PMID: 17412418
- DOI: 10.1016/j.leukres.2007.02.021
Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome
Abstract
The World Health Organization (WHO) assigns myelodysplastic syndrome (MDS) to RA/RCMD/RARS/RSCM/5q- syndrome, if medullary blasts are <5% and peripheral blast (PB) count < or =1%. In 1103 patients with these diagnoses, we analysed survival and risk of AML evolution depending on the presence of PB. Median survival in the group with 1% PB (n=74) was significantly lower as compared to those without PB (20 versus 47 months, p<0.00005). Cumulative risk of AML was significantly higher in patients showing PB (p<0.00005). Median survival of patients with PB was not different from that of RAEB I. We therefore propose to consider patients with PB, regardless of medullary blast, as RAEB I.
Similar articles
-
Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.Leukemia. 1996 Jan;10(1):20-6. Leukemia. 1996. PMID: 8558932
-
Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.Br J Haematol. 2006 Jan;132(2):162-7. doi: 10.1111/j.1365-2141.2005.05853.x. Br J Haematol. 2006. PMID: 16398650
-
Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.Leuk Res. 2004 Jun;28(6):587-94. doi: 10.1016/j.leukres.2003.11.001. Leuk Res. 2004. PMID: 15120935
-
Myelodysplastic syndromes: natural history and features of prognostic importance.Clin Haematol. 1986 Nov;15(4):953-71. Clin Haematol. 1986. PMID: 3552350 Review. No abstract available.
-
Chromosome abnormalities in the myelodysplastic syndromes.Clin Haematol. 1986 Nov;15(4):1003-21. Clin Haematol. 1986. PMID: 3552345 Review. No abstract available.
Cited by
-
Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.Haematologica. 2013 Apr;98(4):568-75. doi: 10.3324/haematol.2012.071449. Epub 2012 Oct 12. Haematologica. 2013. PMID: 23065505 Free PMC article.
-
Utility of peripheral blood flow cytometry in differentiating low grade versus high grade myelodysplastic syndromes (MDS) and in the evaluation of cytopenias.Int J Clin Exp Pathol. 2012;5(3):224-30. Epub 2012 Mar 25. Int J Clin Exp Pathol. 2012. PMID: 22558477 Free PMC article.
-
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.Med Oncol. 2019 Jan 31;36(3):25. doi: 10.1007/s12032-019-1247-3. Med Oncol. 2019. PMID: 30706221 No abstract available.
-
Importance of classical morphology in the diagnosis of myelodysplastic syndrome.Mediterr J Hematol Infect Dis. 2015 May 1;7(1):e2015035. doi: 10.4084/MJHID.2015.035. eCollection 2015. Mediterr J Hematol Infect Dis. 2015. PMID: 25960863 Free PMC article. Review.
-
Higher Level of Peripheral Blood CD34 Positive Cells Presented with Unfavorable Prognosis in Intermediate-Low Risk Acute Promyelocytic Leukemia.Indian J Hematol Blood Transfus. 2020 Apr;36(2):309-315. doi: 10.1007/s12288-019-01232-4. Epub 2019 Dec 17. Indian J Hematol Blood Transfus. 2020. PMID: 32425382 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous